Artificial Pancreas - Medical Devices Pipeline Assessment, 2018

Artificial Pancreas - Medical Devices Pipeline Assessment, 2018


  • Products Id :- GDME0673EPD
  • |
  • Pages: 136
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Artificial Pancreas-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Artificial Pancreas-Medical Devices Pipeline Assessment, 2018" provides an overview of Artificial Pancreas currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Artificial Pancreas under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Artificial Pancreas under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Artificial Pancreas Overview 9

3 Products under Development 10

3.1 Artificial Pancreas-Pipeline Products by Stage of Development 10

3.2 Artificial Pancreas-Pipeline Products by Territory 11

3.3 Artificial Pancreas-Pipeline Products by Regulatory Path 12

3.4 Artificial Pancreas-Pipeline Products by Estimated Approval Date 13

3.5 Artificial Pancreas-Ongoing Clinical Trials 14

4 Artificial Pancreas-Pipeline Products under Development by Companies 15

4.1 Artificial Pancreas Companies-Pipeline Products by Stage of Development 15

4.2 Artificial Pancreas-Pipeline Products by Stage of Development 17

5 Artificial Pancreas Companies and Product Overview 19

5.1 Admetsys Corp Company Overview 19

5.2 Advanced Biosensors-Ohio LLC (Inactive) Company Overview 20

5.3 Animas Corp Company Overview 21

5.4 Beta Bionics Inc Company Overview 22

5.5 Beta-O2 Technologies Ltd Company Overview 27

5.6 Bigfoot Biomedical Inc Company Overview 30

5.7 BioTex Inc Company Overview 31

5.8 Boston University Company Overview 32

5.9 Cerco Medical LLC Company Overview 33

5.10 Converge Biotech, Inc. Company Overview 34

5.11 Covalor Medical, LLC Company Overview 35

5.12 De Montfort University Company Overview 36

5.13 Debiotech SA Company Overview 37

5.14 Defymed SAS Company Overview 38

5.15 Diabeloop Company Overview 39

5.16 DreaMed Diabetes Ltd Company Overview 42

5.17 EOFlow Co Ltd Company Overview 43

5.18 Giner Inc Company Overview 44

5.19 Healios Inc Company Overview 45

5.20 Imperial College London Company Overview 46

5.21 Inreda Diabetic BV Company Overview 47

5.22 Insulet Corp Company Overview 49

5.23 Kencak LLC Company Overview 50

5.24 Medtronic plc Company Overview 51

5.25 Miromatrix Medical Inc Company Overview 61

5.26 Nikkiso Co Ltd Company Overview 62

5.27 Pacific Diabetes Technologies, Inc. Company Overview 63

5.28 Pancreum, LLC Company Overview 64

5.29 PharmaCyte Biotech Inc Company Overview 65

5.30 Polytechnic University of Valencia Company Overview 66

5.31 Rensselaer Polytechnic Institute Company Overview 67

5.32 Senseonics Holdings Inc Company Overview 68

5.33 Tandem Diabetes Care Inc Company Overview 71

5.34 TecMed Inc Company Overview 74

5.35 The Alfred Mann Foundation Company Overview 75

5.36 TypeZero Technologies LLC Company Overview 76

5.37 Ultradian Diagnostics LLC Company Overview 80

5.38 Universidad Autonoma de Madrid Company Overview 81

5.39 University of California San Francisco Company Overview 82

5.40 University of California Santa Barbara Company Overview 83

5.41 University of Cambridge Company Overview 85

5.42 University of Florida Company Overview 87

5.43 University of Newcastle Company Overview 88

5.44 XERIS Pharmaceuticals Inc Company Overview 89

5.45 Yale University Company Overview 90

6 Artificial Pancreas-Recent Developments 91

6.1 Jun 28, 2018: Medtronic Launches the MiniMed 670G System Performance Guarantee for Payers and Employers 91

6.2 Jun 25, 2018: Medtronic secures CE-Mark for MiniMed insulin delivery system 91

6.3 Jun 24, 2018: MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients 92

6.4 Jun 24, 2018: Insulet Presents Positive Clinical Trial Results for the Omnipod Horizon Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions 93

6.5 Jun 23, 2018: Diabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes 94

6.6 Jun 21, 2018: Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed 670G Hybrid Closed Loop System in Children Ages 7-13 95

6.7 Jun 19, 2018: Insulet to Unveil New Omnipod DASH System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions 96

6.8 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 98

7 Appendix 132

7.1 Methodology 132

7.2 About GlobalData 135

7.3 Contact Us 135

7.4 Disclaimer 135

1.2 List of Figures

Figure 1: Artificial Pancreas-Pipeline Products by Stage of Development 11

Figure 2: Artificial Pancreas-Pipeline Products by Territory 12

Figure 3: Artificial Pancreas-Pipeline Products by Regulatory Path 13

Figure 4: Artificial Pancreas-Pipeline Products by Estimated Approval Date 14

Figure 5: Artificial Pancreas-Ongoing Clinical Trials 15

1.1 List of Tables

Table 1: Artificial Pancreas-Pipeline Products by Stage of Development 11

Table 2: Artificial Pancreas-Pipeline Products by Territory 12

Table 3: Artificial Pancreas-Pipeline Products by Regulatory Path 13

Table 4: Artificial Pancreas-Pipeline Products by Estimated Approval Date 14

Table 5: Artificial Pancreas-Ongoing Clinical Trials 15

Table 6: Artificial Pancreas Companies-Pipeline Products by Stage of Development 16

Table 7: Artificial Pancreas-Pipeline Products by Stage of Development 18

Table 8: Admetsys Corp Pipeline Products & Ongoing Clinical Trials Overview 20

Table 9: Admetsys Smart Pancreas-Product Status 20

Table 10: Admetsys Smart Pancreas-Product Description 20

Table 11: Advanced Biosensors-Ohio LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 21

Table 12: Artificial Pancreas-Product Status 21

Table 13: Artificial Pancreas-Product Description 21

Table 14: Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 22

Table 15: Hypoglycemia-Hyperglycemia Minimizer System-Product Status 22

Table 16: Hypoglycemia-Hyperglycemia Minimizer System-Product Description 22

Table 17: Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 18: iLet-Product Status 23

Table 19: iLet-Product Description 23

Table 20: iLet Bionic Pancreas-Insulin-only Version-Product Status 24

Table 21: iLet Bionic Pancreas-Insulin-only Version-Product Description 24

Table 22: Beta Bionics Inc-Ongoing Clinical Trials Overview 25

Table 23: iLet-Bihormonal Bionic Pancreas for the Treatment of Diabetes Post-Pancreatectomy in Children With Congenital Hyperinsulinism-A Pilot Study 26

Table 24: iLet-Feasibility of Outpatient Automated Blood Glucose Control with the Bionic Pancreas for Treatment of Cystic Fibrosis Related Diabetes 26

Table 25: iLet Bionic Pancreas-Insulin-only Version-Home-use Study to Evaluate the Efficacy of Insulin-only Configuration of iLet Bionic Pancreas System in Subjects with Type I Diabetes 27

Table 26: Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

Table 27: Air Bio-artificial Pancreas-Product Status 28

Table 28: Air Bio-artificial Pancreas-Product Description 28

Table 29: Beta-O2 Technologies Ltd-Ongoing Clinical Trials Overview 29

Table 30: Air Bio-artificial Pancreas-An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 30

Table 31: Bigfoot Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 31

Table 32: Smartloop Automated Insulin Delivery System-Product Status 31

Table 33: Smartloop Automated Insulin Delivery System-Product Description 31

Table 34: BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 35: Artificial Pancreas-Product Status 32

Table 36: Artificial Pancreas-Product Description 32

Table 37: Boston University Pipeline Products & Ongoing Clinical Trials Overview 33

Table 38: Bionic Pancreas-Product Status 33

Table 39: Bionic Pancreas-Product Description 33

Table 40: Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 34

Table 41: Islet Sheet-Product Status 34

Table 42: Islet Sheet-Product Description 34

Table 43: Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

Table 44: Bioartificial Pancreas System-Product Status 35

Table 45: Bioartificial Pancreas System-Product Description 35

Table 46: Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 36

Table 47: Artificial Pancreas-Product Status 36

Table 48: Artificial Pancreas-Product Description 36

Table 49: De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 37

Table 50: InSmart Artificial Pancreas-Product Status 37

Table 51: InSmart Artificial Pancreas-Product Description 37

Table 52: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 38

Table 53: Next Generation Artificial Pancreas-Product Status 38

Table 54: Next Generation Artificial Pancreas-Product Description 38

Table 55: Defymed SAS Pipeline Products & Ongoing Clinical Trials Overview 39

Table 56: MAILPAN-Product Status 39

Table 57: MAILPAN-Product Description 39

Table 58: Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 40

Table 59: Diabeloop Artificial Pancreas-Product Status 40

Table 60: Diabeloop Artificial Pancreas-Product Description 40

Table 61: Diabeloop-Ongoing Clinical Trials Overview 41

Table 62: Diabeloop Artificial Pancreas-Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison with Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes 42

Table 63: DreaMed Diabetes Ltd Pipeline Products & Ongoing Clinical Trials Overview 43

Table 64: Glucositter-Product Status 43

Table 65: Glucositter-Product Description 43

Table 66: EOFlow Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 44

Table 67: Disposable Artificial Pancreas System-Product Status 44

Table 68: Disposable Artificial Pancreas System-Product Description 44

Table 69: Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Table 70: BAPIOS System-Product Status 45

Table 71: BAPIOS System-Product Description 45

Table 72: Healios Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Table 73: Bioengineered Pancreas-Product Status 46

Table 74: Bioengineered Pancreas-Product Description 46

Table 75: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 47

Table 76: Bio-inspired Artificial Pancreas-Product Status 47

Table 77: Bio-inspired Artificial Pancreas-Product Description 47

Table 78: Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 48

Table 79: Bi-Hormonal Artificial Pancreas-Product Status 48

Table 80: Bi-Hormonal Artificial Pancreas-Product Description 48

Table 81: Bi-Hormonal Artificial Pancreas-Lighter Version-Product Status 49

Table 82: Bi-Hormonal Artificial Pancreas-Lighter Version-Product Description 49

Table 83: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 50

Table 84: Omnipod Horizon Hybrid Closed Loop System-Product Status 50

Table 85: Omnipod Horizon Hybrid Closed Loop System-Product Description 50

Table 86: Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 51

Table 87: BioArtificial Pancreas-Product Status 51

Table 88: BioArtificial Pancreas-Product Description 51

Table 89: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 52

Table 90: MiniMed 640G System-Product Status 52

Table 91: MiniMed 640G System-Product Description 53

Table 92: MiniMed 670G-Product Status 53

Table 93: MiniMed 670G-Product Description 53

Table 94: Third-Generation Artificial Pancreas System-Product Status 54

Table 95: Third-Generation Artificial Pancreas System-Product Description 54

Table 96: Medtronic plc-Ongoing Clinical Trials Overview 55

Table 97: MiniMed 670G-A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults with Type 1 Diabetes 56

Table 98: MiniMed 670G-A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation 56

Table 99: MiniMed 670G-Clinical Startup of the 670G Closed Loop Insulin Delivery System 56

Table 100: MiniMed 670G-Effect of Hybrid Closed-loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-arm Clinical Trial 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Admetsys Corp

Advanced Biosensors-Ohio LLC

Animas Corp

Beta Bionics Inc

Beta-O2 Technologies Ltd

Bigfoot Biomedical Inc

BioTex Inc

Boston University

Cerco Medical LLC

Converge Biotech, Inc.

Covalor Medical, LLC

De Montfort University

Debiotech SA

Defymed SAS

Diabeloop

DreaMed Diabetes Ltd

EOFlow Co Ltd

Giner Inc

Healios Inc

Imperial College London

Inreda Diabetic BV

Insulet Corp

Kencak LLC

Medtronic plc

Miromatrix Medical Inc

Nikkiso Co Ltd

Pacific Diabetes Technologies, Inc.

Pancreum, LLC

PharmaCyte Biotech Inc

Polytechnic University of Valencia

Rensselaer Polytechnic Institute

Senseonics Holdings Inc

Tandem Diabetes Care Inc

TecMed Inc

The Alfred Mann Foundation

TypeZero Technologies LLC

Ultradian Diagnostics LLC

Universidad Autonoma de Madrid

University of California San Francisco

University of California Santa Barbara

University of Cambridge

University of Florida

University of Newcastle

XERIS Pharmaceuticals Inc

Yale University

Admetsys Corp, Admetsys Smart Pancreas; Advanced Biosensors-Ohio LLC (Inactive), Artificial Pancreas; Animas Corp, Hypoglycemia-Hyperglycemia Minimizer System; Beta Bionics Inc, iLet; Beta Bionics Inc, iLet Bionic Pancreas - Insulin-only Version; Beta-O2 Technologies Ltd, Air Bio-artificial Pancreas; Bigfoot Biomedical Inc, Smartloop Automated Insulin Delivery System; BioTex Inc, Artificial Pancreas; Boston University, Bionic Pancreas; Cerco Medical LLC, Islet Sheet; Converge Biotech, Inc., Bioartificial Pancreas System; Covalor Medical, LLC, Artificial Pancreas; De Montfort University, InSmart Artificial Pancreas; Debiotech SA, Next Generation Artificial Pancreas; Defymed SAS, MAILPAN; Diabeloop, Diabeloop Artificial Pancreas; DreaMed Diabetes Ltd, Glucositter; EOFlow Co Ltd, Disposable Artificial Pancreas System; Giner Inc, BAPIOS System; Healios Inc, Bioengineered Pancreas; Imperial College London, Bio-inspired Artificial Pancreas; Inreda Diabetic BV, Bi-Hormonal Artificial Pancreas; Inreda Diabetic BV, Bi-Hormonal Artificial Pancreas - Lighter Version; Insulet Corp, Omnipod Horizon Hybrid Closed Loop System; Kencak LLC, BioArtificial Pancreas; Medtronic plc, MiniMed 640G System; Medtronic plc, MiniMed 670G; Medtronic plc, Third-Generation Artificial Pancreas System; Miromatrix Medical Inc, Miro Pancreas; Nikkiso Co Ltd, Artificial Pancreas; Pacific Diabetes Technologies, Inc., Artificial Endocrine Pancreas; Pancreum, LLC, Genesis Artificial Pancreas; PharmaCyte Biotech Inc, Bio-Artificial Pancreas; Polytechnic University of Valencia, Closed-loop Control System; Rensselaer Polytechnic Institute, Closed-Loop Artificial Pancreas System; Senseonics Holdings Inc, Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump; Tandem Diabetes Care Inc, t:slim X2 Pump With Dexcom G6 and HCL; TecMed Inc, TecMed Artificial Pancreas; The Alfred Mann Foundation, Implantable Artificial Pancreas Device; TypeZero Technologies LLC, inControl; Ultradian Diagnostics LLC, Artificial Pancreas; Universidad Autonoma de Madrid, Predictive Rule-Based Algorithm; University of California San Francisco, Implantable Bioartificial Pancreas; University of California Santa Barbara, Closed-Loop Artificial Pancreas; University of California Santa Barbara, Pediatric Artificial Pancreas; University of Cambridge, Artificial Pancreas; University of Cambridge, Florence D2A System; University of Florida, Bioartificial Pancreas - Type 1 Diabetes; University of Newcastle, Closed Glucose-Sensing Insulin-Delivery System; XERIS Pharmaceuticals Inc, G-Pump - BP; Yale University, Automated Insulin Delivery System

select a license
Single User License
USD 4000 INR 274480
Site License
USD 8000 INR 548960
Corporate User License
USD 12000 INR 823440

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com